Nalaganje...
Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial.
Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus...
Shranjeno v:
| izdano v: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6504613/ https://ncbi.nlm.nih.gov/pubmed/30724455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13655 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|